Roth Capital Reiterates “Buy” Rating for LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “buy” rating reaffirmed by stock analysts at Roth Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $108.00 price objective on the medical instruments supplier’s stock. Roth Capital’s price target suggests a potential upside of 24.36% from the stock’s current price.

LMAT has been the subject of a number of other reports. Barrington Research reiterated an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Cantor Fitzgerald increased their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $100.60.

LeMaitre Vascular Price Performance

Shares of LMAT traded down $0.42 during mid-day trading on Wednesday, reaching $86.85. 51,901 shares of the stock traded hands, compared to its average volume of 181,379. The firm has a fifty day moving average price of $90.13 and a 200 day moving average price of $87.01. The company has a market cap of $1.97 billion, a price-to-earnings ratio of 42.16, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $63.15 million for the quarter, compared to analysts’ expectations of $62.48 million. During the same period last year, the firm earned $0.52 earnings per share. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, equities research analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director John A. Roush sold 6,561 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the sale, the director owned 2,916 shares in the company, valued at $269,875.80. The trade was a 69.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 10,815 shares of the business’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director owned 17,976 shares in the company, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 20,815 shares of company stock worth $1,929,206. 9.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. lifted its position in LeMaitre Vascular by 3.0% during the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock valued at $9,385,000 after acquiring an additional 3,248 shares during the last quarter. US Bancorp DE grew its position in LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 368 shares during the period. Northern Trust Corp grew its position in LeMaitre Vascular by 5.4% during the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock valued at $28,993,000 after buying an additional 17,748 shares during the period. Congress Asset Management Co. grew its position in shares of LeMaitre Vascular by 4.6% in the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after purchasing an additional 29,553 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of LeMaitre Vascular in the second quarter worth about $892,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.